Literature DB >> 10973254

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

K B Lane, R D Machado, M W Pauciulo, J R Thomson, J A Phillips, J E Loyd, W C Nichols, R C Trembath.   

Abstract

Primary pulmonary hypertension (PPH), characterized by obstruction of pre-capillary pulmonary arteries, leads to sustained elevation of pulmonary arterial pressure (mean >25 mm Hg at rest or >30 mm Hg during exercise). The aetiology is unknown, but the histological features reveal proliferation of endothelial and smooth muscle cells with vascular remodelling (Fig. 1). More than one affected relative has been identified in at least 6% of cases (familial PPH, MIM 178600). Familial PPH (FPPH) segregates as an autosomal dominant disorder with reduced penetrance and has been mapped to a locus designated PPH1 on 2q33, with no evidence of heterogeneity. We now show that FPPH is caused by mutations in BMPR2, encoding a TGF-beta type II receptor (BMPR-II). Members of the TGF-beta superfamily transduce signals by binding to heteromeric complexes of type I and II receptors, which activates serine/threonine kinases, leading to transcriptional regulation by phosphorylated Smads. By comparison with in vitro studies, identified defects of BMPR-II in FPPH are predicted to disrupt ligand binding, kinase activity and heteromeric dimer formation. Our data demonstrate the molecular basis of FPPH and underscore the importance in vivo of the TGF-beta signalling pathway in the maintenance of blood vessel integrity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973254     DOI: 10.1038/79226

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  433 in total

Review 1.  The genetics of systemic sclerosis.

Authors:  Randall W Johnson; Monty B Tew; Frank C Arnett
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 2.  Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension.

Authors:  M Rabinovitch
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 3.  Pulmonary hypertension in the young.

Authors:  Sheila G Haworth
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

4.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 5.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

Review 6.  Lung organogenesis.

Authors:  David Warburton; Ahmed El-Hashash; Gianni Carraro; Caterina Tiozzo; Frederic Sala; Orquidea Rogers; Stijn De Langhe; Paul J Kemp; Daniela Riccardi; John Torday; Saverio Bellusci; Wei Shi; Sharon R Lubkin; Edwin Jesudason
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

Review 7.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 8.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

9.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

Authors:  S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

10.  Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.

Authors:  Chiara Federici; Kylie M Drake; Christina M Rigelsky; Lauren N McNelly; Sirena L Meade; Suzy A A Comhair; Serpil C Erzurum; Micheala A Aldred
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.